News
DXR
9.55
+0.42%
0.04
BRIEF-Daxor Corporation Announces Closing Of $2.1 Mln Underwritten Public Offering
Reuters · 11/17 22:29
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
Oak Ridge, TN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering con...
GlobeNewswire · 11/17 16:07
TUSK, ZH and CHRA among mid-day movers
Seekingalpha · 11/15 18:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 11/15 17:32
Nu Holdings among financials gainers, Capital One Financial in losers pack
Seekingalpha · 11/15 17:00
Dow Surges More Than 300 Points After Producer Prices Increase Less Than Expected
Benzinga · 11/15 15:12
Daxor to raise $2M in stock offering
Seekingalpha · 11/15 13:59
Daxor Corporation Announces Pricing of $2.0 million Underwritten Public Offering
Oak Ridge, TN, Nov. 15, 2022 (GLOBE NEWSWIRE) -- DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of an underwritten public offering consisting of 210,527 sha...
GlobeNewswire · 11/15 13:45
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 11/15 13:31
Daxor Prices $2 Million Common Stock Offering
Daxor Prices $2 Million Common Stock Offering
MT Newswires · 11/15 11:07
Daxor tumbles 11% aftermarket on proposed stock offering
Seekingalpha · 11/14 22:28
Newly Published Study Demonstrates Significant Clinical Utility Of Daxor's Blood Volume Diagnostic In The Evaluation Of Heart Failure
Benzinga · 11/03 12:26
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
Oak Ridge, TN, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart Association Scientific Sessions (AHA) at McCormick Place Con...
GlobeNewswire · 10/31 12:00
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
Evidence Presented Utilizing Daxor’s BVA-100® Blood Volume Test Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that a scientific session titled “De...
GlobeNewswire · 10/05 12:30
Study Data From Mayo Clinic On Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented At Key Scientific Meeting On October 2nd; More Than 50% Discharged From Hospital With Suboptimal Treatment
Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in
Benzinga · 10/04 12:04
BRIEF-Daxor Corp - New Data Validating Benefits Of Company's Bva-100 Diagnostic Blood Test
BRIEF-Daxor Corp - New Data Validating Benefits Of Company's Bva-100 Diagnostic Blood Test
Reuters · 10/03 13:35
BRIEF-New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With Bva-Guided Care
BRIEF-New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With Bva-Guided Care
Reuters · 10/03 13:06
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume measurement technology, today announces new data validating th...
GlobeNewswire · 10/03 13:00
New Studies Validating The Uniqueness Of The BVA-100 Blood Test For Heart Failure Patients Compared To Pressure Measures; Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor
Benzinga · 10/03 12:46
BRIEF-Daxor Co Announces New Data From Duke Heart Validating Benefits Of Co's Bva-100 Blood Test In Optimizing Individualized Therapy For Heart Failure Patients
BRIEF-Daxor Co Announces New Data From Duke Heart Validating Benefits Of Co's Bva-100 Blood Test In Optimizing Individualized Therapy For Heart Failure Patients
Reuters · 10/03 12:34
More
Webull provides a variety of real-time DXR stock news. You can receive the latest news about DAXOR CORP through multiple platforms. This information may help you make smarter investment decisions.
About DXR
Daxor Corporation is a medical instrumentation and biotechnology company. The Company is focused on blood volume measurement. The Company has developed and marketed the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the food and drug administration (FDA) to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a broad range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. It has ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the National Institutes of Health (NIH) and is under contract developing analyzers.